Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer
 

A new study has shown that AstraZeneca's Lynparza (olaparib) can significantly slow the progress of breast cancer that is caused partially due to mutations of the culprit gene called BRCA. BRCA gene mutations are responsible for around 3% of all breast cancers. These cases of the disease that have a basis in the gene are notoriously difficult to treat and women who are tested positive for this gene may even opt for removal of their breasts before even the cancer strikes. Noted actress Angelina Jolie went for a similar prophylactic mastectomy.

More...